S

Syntax Bio

HealthBiotechnologyB2B📍 United States

Syntax Bio is a biotechnology company focused on developing innovative therapies for genetic diseases. The company aims to address unmet medical needs through its proprietary technology platform. This funding round will help expand its leadership team and board members, enhancing its strategic direction.

Total raised
$14.4M
tracked to date
Latest round
Series A
Jun 21, 2026
Press coverage
2
outlets tracked

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. 1
    $14.4MSeries AJun 21, 2026
    Announcement ↗

Syntax Bio in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile

Syntax Bio — Health startup in United States | Datapile